• Cadrenal reported Phase 2 data for CAD-1005 in HIT showing an absolute reduction of more than 25% in thrombotic events.
• Thrombotic events fell to 50% on CAD-1005 versus more than 75% on placebo; the trial was not powered for statistical significance.
• Safety readout showed no serious adverse events attributed to CAD-1005, no major bleeding in SRA+ patients, no deaths.
• Results support advancing the program toward a pivotal Phase 3 registration trial.
• CAD-1005 holds FDA Orphan Drug and Fast Track designations, with EMA Orphan Drug status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130900PRIMZONEFULLFEED9761086) on July 13, 2026, and is solely responsible for the information contained therein.